Anticancer Drugs Practice Questions

Q: A patient with HER2-positive breast cancer is resistant to trastuzumab. Which other targeted therapy could be considered?

Lapatinib. ***Lapatinib*** - **Lapatinib** is a dual tyrosine kinase inhibitor that targets both **HER1 (EGFR)** and **HER2**, providing an alternative mechanism of action that can be effective in some trastuzumab-resistant cases. - Its ability to inhibit the intracellular phosphorylation of these receptors helps to overcome resistance pathways that may develop with trastuzumab, which primarily targets the extracellular domain of HER2. *Bevacizumab* - **Bevacizumab** is a **monoclonal antibody** that targets **VEGF (vascular endothelial growth factor)**, inhibiting angiogenesis. - It is used in certain types of cancer but does not directly target HER2 or HER1 pathways, making it less effective for trastuzumab-resistant HER2-positive breast cancer. *Cetuximab* - **Cetuximab** is a monoclonal antibody that targets the **epidermal growth factor receptor (EGFR or HER1)**, but not HER2. - While it targets a related receptor, its specificity for HER1 means it would not be an appropriate choice for HER2-positive breast cancer, particularly in a trastuzumab-resistant setting. *Imatinib* - **Imatinib** is a **tyrosine kinase inhibitor** primarily used in **chronic myeloid leukemia (CML)** and **gastrointestinal stromal tumors (GIST)**. - It targets the **BCR-ABL fusion protein** and **KIT (CD117)**, which are not relevant therapeutic targets in HER2-positive breast cancer.

Q: Which class of chemotherapy drugs inhibits the enzyme topoisomerase I, resulting in DNA damage and cancer cell death?

Topoisomerase I inhibitors. ***Topoisomerase I inhibitors*** - **Topoisomerase I inhibitors** like **irinotecan** and **topotecan** specifically target and inhibit **DNA Topoisomerase I**, preventing it from rejoining single-strand breaks. - This inhibition leads to the accumulation of **single-strand DNA breaks**, which are converted into lethal **double-strand breaks** during DNA replication, inducing **apoptosis** in cancer cells. *Vinca alkaloids* - **Vinca alkaloids** (e.g., **vincristine**, **vinblastine**) are **microtubule-targeting agents** that bind to **tubulin** and inhibit its polymerization, thus disrupting spindle formation during mitosis. - Their primary mechanism is **mitotic arrest** at the metaphase stage, not direct inhibition of topoisomerase enzymes. *Taxanes* - **Taxanes** (e.g., **paclitaxel**, **docetaxel**) are also **microtubule-targeting agents** that, unlike vinca alkaloids, stabilize microtubules and prevent their depolymerization. - This stabilization gums up the cell's machinery, leading to **mitotic arrest** and subsequent **apoptosis**. *Topoisomerase II inhibitors* - **Topoisomerase II inhibitors** (e.g., **etoposide**, **doxorubicin**) target and inhibit **DNA Topoisomerase II**, an enzyme that creates and reseals **double-strand DNA breaks**. - While they do cause DNA damage, their mechanism is distinct from Topoisomerase I inhibitors as they interfere with the religation step of **double-strand breaks**, not single-strand breaks.

Q: Which chemotherapeutic agent is primarily associated with cardiotoxicity, particularly manifesting as dilated cardiomyopathy?

Doxorubicin. ***Doxorubicin*** - **Doxorubicin** is a well-known **anthracycline chemotherapeutic agent** with a significant risk of **dose-dependent cardiotoxicity**. - This cardiotoxicity primarily manifests as **dilated cardiomyopathy**, leading to progressive heart failure and ventricular dysfunction. *Vincristine* - **Vincristine** is a **vinca alkaloid** primarily associated with **neurotoxicity**, causing peripheral neuropathies, muscle weakness, and autonomic dysfunction. - While it can have some cardiac effects, **dilated cardiomyopathy** is not its primary or most common cardiotoxic manifestation. *Methotrexate* - **Methotrexate** is an **antimetabolite** primarily associated with toxicity to rapidly dividing cells, leading to **mucositis**, **myelosuppression**, and **hepatotoxicity**. - Although rare, it can cause pericardial effusion or myocarditis, but not typically **dilated cardiomyopathy**. *Cisplatin* - **Cisplatin** is a **platinum-based chemotherapeutic agent** primarily associated with **nephrotoxicity**, **ototoxicity**, and **neurotoxicity**. - While it can rarely cause electrolyte disturbances that indirectly affect cardiac function, **dilated cardiomyopathy** is not a primary or direct cardiotoxic effect.

Q: A patient with chronic myeloid leukemia (CML) is being treated with a drug that specifically inhibits the BCR-ABL tyrosine kinase. Which of the following drugs was the FIRST tyrosine kinase inhibitor approved for first-line treatment of this condition?

Imatinib. ***Imatinib*** - **Imatinib** was the **first tyrosine kinase inhibitor (TKI)** specifically targeting the **BCR-ABL fusion protein** in CML, approved in 2001. - It revolutionized CML treatment by significantly improving patient outcomes and converting a previously fatal disease into a manageable chronic condition. - While second-generation TKIs are now also approved as first-line options, imatinib holds the distinction of being the **original breakthrough drug** for CML. *Dasatinib* - **Dasatinib** is a **second-generation TKI** approved later (2006) for CML. - Now approved as a first-line option alongside imatinib, but was **not the first** TKI developed for this indication. - Often preferred in patients with high-risk disease or specific mutations. *Nilotinib* - **Nilotinib** is also a **second-generation TKI** approved after imatinib (2007). - Currently approved as a first-line alternative to imatinib, particularly effective with fewer progression events. - However, it was **not the original** first-line TKI for CML. *All of the options* - While all three drugs are now accepted as **first-line treatment options** in current guidelines, the question asks which was the **FIRST** TKI approved. - **Imatinib** holds the unique historical distinction of being the pioneering drug that transformed CML therapy.

Q: A patient with cancer is administered a chemotherapy drug that inhibits topoisomerase I, resulting in DNA strand breaks. Which drug is used?

Irinotecan. This is an excellent question that tests your knowledge of chemotherapy mechanisms. Let’s break down each option: ***Irinotecan*** - **Irinotecan** is a **topoisomerase I inhibitor**, which prevents DNA unwinding, leading to **DNA strand breaks** and ultimately cell death. - It is a **camptothecin derivative** commonly used in the treatment of **colorectal cancer**. *Doxorubicin* - **Doxorubicin** is an **anthracycline antibiotic** that intercalates into DNA, inhibiting topoisomerase II and generating free radicals. - While it affects topoisomerase, its primary mechanism involves **topoisomerase II inhibition**, not topoisomerase I. *Vincristine* - **Vincristine** is a **vinca alkaloid** that works by binding to **tubulin**, thereby inhibiting microtubule formation and disrupting the mitotic spindle. - Its mechanism is entirely different from topoisomerase inhibition, as it primarily targets **microtubule dynamics** during cell division. *Etoposide* - **Etoposide** is a **topoisomerase II inhibitor**, meaning it interferes with the enzyme responsible for relaxing supercoiled DNA by breaking and rejoining both DNA strands. - While it does cause **DNA strand breaks**, it specifically targets **topoisomerase II**, not topoisomerase I.

Q: A patient is treated with a chemotherapy agent that inhibits microtubule assembly and disrupts cell division. Which drug is appropriate?

Vincristine. ***Correct: Vincristine*** **Vincristine** is a **vinca alkaloid** that works by **inhibiting microtubule assembly**, which is crucial for the formation of the mitotic spindle during cell division. By binding to **tubulin**, vincristine prevents microtubule polymerization, thereby arresting cells in **metaphase** and disrupting mitosis. This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells. *Incorrect: Cyclophosphamide* **Cyclophosphamide** is an **alkylating agent** that forms covalent bonds with DNA, causing **DNA cross-linking and strand breaks**. It primarily interferes with DNA replication and transcription, rather than affecting microtubule assembly or function. *Incorrect: Doxorubicin* **Doxorubicin** is an **anthracycline antibiotic** that works by **intercalating into DNA** and inhibiting **topoisomerase II**. It also generates **free radicals** causing oxidative damage. Its primary mechanism involves DNA damage and interference with DNA synthesis, not microtubule disruption. *Incorrect: Cisplatin* **Cisplatin** is a **platinum-based alkylating agent** that forms **intrastrand and interstrand DNA cross-links**. These DNA adducts inhibit DNA replication and transcription, leading to apoptosis. It does not directly target microtubules or affect microtubule assembly.

Q: All-trans retinoic acid is primarily used in the treatment of which of the following tumors?

PML-RARA. ***PML-RARA*** - **All-trans retinoic acid (ATRA)** is a cornerstone treatment for **acute promyelocytic leukemia (APML)**, which is characterized by the **PML-RARA fusion gene**. - ATRA works by inducing differentiation of leukemic promyelocytes, overcoming the maturation block caused by the **PML-RARA** oncoprotein. *BCR-ABL* - The **BCR-ABL fusion gene** is characteristic of **chronic myeloid leukemia (CML)**, and sometimes in acute lymphoblastic leukemia (ALL). - The primary treatment for **BCR-ABL positive leukemias** involves **tyrosine kinase inhibitors (TKIs)**, such as imatinib, not ATRA. *CMYC* - **CMYC** is an oncogene whose dysregulation is frequently implicated in various cancers, including **Burkitt lymphoma** and some forms of acute myeloid leukemia (AML). - There is no direct therapeutic role for ATRA specifically targeting tumors driven by **CMYC overexpression**. *CEBPA* - **CEBPA** mutations are found in a subset of **acute myeloid leukemia (AML)**, often leading to a favorable prognosis. - While ATRA can be used in some AML subtypes, it is not specifically indicated or primarily effective for AML characterized solely by **CEBPA mutations**; its role is specific to **PML-RARA**.

Q: Drug of choice for palliative treatment of pancreatic carcinoma

Gemcitabine. ***Gemcitabine*** - **Gemcitabine** is the cornerstone chemotherapy agent and standard **first-line drug of choice** for palliative treatment of advanced pancreatic cancer [1]. - It demonstrates significant **palliative benefits** by improving quality of life, clinical benefit response, and modest survival extension compared to 5-FU. - Its mechanism involves interfering with DNA synthesis as a nucleoside analog, leading to cell death in rapidly dividing cancer cells [1]. - For patients with good performance status, gemcitabine-based combination regimens (such as with nab-paclitaxel) may offer additional benefit, but gemcitabine remains the foundational agent. *Erlotinib* - **Erlotinib** is a tyrosine kinase inhibitor targeting the **epidermal growth factor receptor (EGFR)** [2]. - It may be used in combination with gemcitabine for advanced pancreatic cancer, but provides only modest additional benefit. - It is not the primary drug of choice for palliative treatment alone. *Paclitaxel* - **Paclitaxel** is a taxane chemotherapy agent; specifically, **nab-paclitaxel (albumin-bound paclitaxel)** is used in combination with gemcitabine as a first-line regimen for metastatic pancreatic cancer. - The nab-paclitaxel plus gemcitabine combination has shown superior outcomes compared to gemcitabine monotherapy in clinical trials. - However, as a single agent for palliative treatment, paclitaxel is not the drug of choice; gemcitabine remains the foundational agent. *Cyclophosphamide* - **Cyclophosphamide** is an alkylating agent used in various cancers like leukemia, lymphoma, and some solid tumors. - It has no established role in the treatment of pancreatic carcinoma and is not used for palliative therapy in this disease.

Q: Which of the following antineoplastic agents is primarily used in the management of small cell carcinoma of the lung?

Cisplatin. ***Cisplatin*** - **Cisplatin** is a platinum-based chemotherapy drug that is a cornerstone of treatment for **small cell lung carcinoma (SCLC)**, often used in combination with etoposide. - It works by forming **DNA adducts**, leading to cross-linking and inhibition of DNA synthesis, which is particularly effective against rapidly dividing SCLC cells. *Bleomycin* - **Bleomycin** is an antibiotic antineoplastic agent primarily used in germ cell tumors, lymphomas, and head and neck cancers, but not typically as a first-line agent for SCLC. - Its main dose-limiting toxicity is **pulmonary fibrosis**, which can be severe and is a significant concern. *Paclitaxel* - **Paclitaxel** is a **taxane** chemotherapy drug mainly used in non-small cell lung cancer, ovarian cancer, and breast cancer. - It stabilizes microtubules, preventing depolymerization, which leads to cell cycle arrest and apoptosis, but is not a primary agent for SCLC. *Doxorubicin* - **Doxorubicin** is an **anthracycline antibiotic** used for various cancers including lymphomas, breast cancer, and sarcomas, but not a primary chemotherapy for SCLC. - Its significant side effect is **cardiotoxicity**, which can lead to congestive heart failure.

Q: Which of the following conditions is Cetuximab primarily used to treat?

Colorectal cancer. ***Colorectal cancer*** - **Cetuximab** is an **epidermal growth factor receptor (EGFR) inhibitor** primarily used in the treatment of metastatic colorectal cancer. - It is particularly effective in patients with **RAS wild-type tumors**, as mutations in RAS can confer resistance to anti-EGFR therapies. *Basal cell carcinoma* - This is a **skin cancer** typically treated with local excision, topical therapies, or hedgehog pathway inhibitors like vismodegib or sonidegib. - **Cetuximab** is not a standard treatment for basal cell carcinoma. *Crohn's disease* - This is an **inflammatory bowel disease** treated with anti-inflammatory drugs, immunomodulators, and biologics like anti-TNF agents (e.g., adalimumab, infliximab). - **Cetuximab** targets EGFR and is not indicated for Crohn's disease. *Adamantinoma of bone* - This is a rare, low-grade malignant **bone tumor** that is typically treated with surgical resection. - There is no established role for **Cetuximab** in the management of adamantinoma.

Question 1

A patient with HER2-positive breast cancer is resistant to trastuzumab. Which other targeted therapy could be considered?

Accepted Answer

Lapatinib

Answer

Bevacizumab

Answer

Imatinib

Answer

Cetuximab

Question 2

Which class of chemotherapy drugs inhibits the enzyme topoisomerase I, resulting in DNA damage and cancer cell death?

Accepted Answer

Topoisomerase I inhibitors

Answer

Vinca alkaloids

Answer

Taxanes

Answer

Topoisomerase II inhibitors

Question 3

Which chemotherapeutic agent is primarily associated with cardiotoxicity, particularly manifesting as dilated cardiomyopathy?

Accepted Answer

Doxorubicin

Answer

Methotrexate

Answer

Vincristine

Answer

Cisplatin

Question 4

A patient with chronic myeloid leukemia (CML) is being treated with a drug that specifically inhibits the BCR-ABL tyrosine kinase. Which of the following drugs was the FIRST tyrosine kinase inhibitor approved for first-line treatment of this condition?

Accepted Answer

Imatinib

Answer

Dasatinib

Answer

Nilotinib

Answer

All of the options

Question 5

A patient with cancer is administered a chemotherapy drug that inhibits topoisomerase I, resulting in DNA strand breaks. Which drug is used?

Accepted Answer

Irinotecan

Answer

Doxorubicin

Answer

Vincristine

Answer

Etoposide

Question 6

A patient is treated with a chemotherapy agent that inhibits microtubule assembly and disrupts cell division. Which drug is appropriate?

Accepted Answer

Vincristine

Answer

Cyclophosphamide

Answer

Doxorubicin

Answer

Cisplatin

Question 7

All-trans retinoic acid is primarily used in the treatment of which of the following tumors?

Accepted Answer

PML-RARA

Answer

BCR-ABL

Answer

CMYC

Answer

CEBPA

Question 8

Drug of choice for palliative treatment of pancreatic carcinoma

Accepted Answer

Gemcitabine

Answer

Cyclophosphamide

Answer

Erlotinib

Answer

Paclitaxel

Question 9

Which of the following antineoplastic agents is primarily used in the management of small cell carcinoma of the lung?

Accepted Answer

Cisplatin

Answer

Bleomycin

Answer

Paclitaxel

Answer

Doxorubicin

Question 10

Which of the following conditions is Cetuximab primarily used to treat?

Accepted Answer

Colorectal cancer

Answer

Basal cell carcinoma

Answer

Crohn's disease

Answer

Adamantinoma of bone

Anticancer Drugs — MCQs

Anticancer Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?